- MetAlert recently signed a Letter of Intent to acquire Florida-based TrakTec in a cash and stock deal worth $4.5 million
- TrakTec manufactures and sells affordable location awareness technology solutions for consumer, enterprise, and government applications
- The planned acquisitions will bring on board synergistic and complementary technologies that fit in with MetAlert’s subscription model and existing suite of location-sensitive and tracking solutions
- The acquisition is also set to offer both short- and long-term benefits, eventually contributing to the company’s efforts to up-list
MetAlert (OTC: MLRT), a pioneer in location-sensitive wearable technology products and human and health monitoring devices, is looking to achieve “some big things” in 2023. Speaking in an interview with Sequire Spotlight published December 28, CEO Patrick Bertagna outlined the company’s strategic plans for 2023 (https://ibn.fm/S0D3z). MetAlert, he explained, is “looking at making some acquisitions, bringing on some new products, and possibly doing an up-list,” with the acquisitions, in particular, intended to align with the company’s existing subscription model and increase the revenue per user (“RPU”). And as the RPU increases, Bertagna continued, the company’s margins and overall revenues will also increase, which “hopefully will put us in a position to up-list.”
In what perfectly captures and exemplifies Bertagna’s statement, MetAlert on January 11 announced it had signed a Letter of Intent (“LOI”) to acquire TrakTec LLC, a Florida-based manufacturer and seller of affordable location awareness technology solutions for consumer, enterprise, and…
NOTE TO INVESTORS: The latest news and updates relating to MLRT are available in the company’s newsroom at https://ibn.fm/MLRT
About BioMedWire
BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to millions of social media followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “Biotech” to 844-397-5787 (U.S. Mobile Phones Only)
For more information, please visit https://www.biomedwire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
BioMedWire (BMW)
San Francisco, California
www.biomedwire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is part of the InvestorBrandNetwork.
